{"product_id":"89bio-swot-analysis","title":"89bio SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e89bio shows promise with its targeted metabolic and dermatology pipeline and strong scientific partnerships, but faces clinical, regulatory, and funding risks that could reshape its trajectory.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis for a research-backed, investor-ready report—Word and editable Excel deliverables included to support valuation, strategy, and pitch preparation; purchase now to unlock detailed insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin’s Best-in-Class Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin, 89bio’s engineered FGF21 analog, showed in Phase 2b a 32% absolute NASH resolution rate (p\u0026lt;0.01) and a 25% fibrosis improvement (≥1 stage, p\u0026lt;0.05), signaling superior efficacy versus historical comparators; its metabolic mechanism targets insulin resistance and lipid handling, addressing root causes of MASH; this dual-action profile supports peak sales estimates of $2–4B in some models and strong positioning in a high unmet-need market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Clinical Pipeline with Phase 3 Depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, 89bio had multiple Phase 3 programs, including ENLIGHTEN 1\/2 for MASH (metabolic dysfunction-associated steatohepatitis) and ENTRUST for severe hypertriglyceridemia, positioning several late-stage readouts in 2025–2026; this increases chances for regulatory approvals and partner interest. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alignment with Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio has secured alignment with the FDA and EMA on its Phase 3 design and accelerated approval pathways, cutting typical late-stage regulatory uncertainty and creating a clear route to Biologics License Application (BLA) filings; regulatory clarity can shorten time-to-market by 6–18 months and, for comparable liver NASH programs, improved approval probability from ~12% to ~25%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid Financial Position and Cash Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing successful early-2025 financings, 89bio held over 500 million dollars in cash and marketable securities by mid-2025, giving a runway into 2027 that covers planned Phase 3 trial expenses and initial commercial prep.\u003c\/p\u003e\n\u003cp\u003eThis strong balance sheet reduces near-term dilution risk, supports enrollment and manufacturing scale-up, and allows strategic flexibility during the costly end-stage of drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: \u0026gt;500 million (mid-2025)\u003c\/li\u003e\n\u003cli\u003eRunway: funded into 2027\u003c\/li\u003e\n\u003cli\u003eCovers: Phase 3 costs + initial commercial prep\u003c\/li\u003e\n\u003cli\u003eBenefit: lowers dilution, increases strategic optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing and Scale-Up Readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio has invested in commercial-scale manufacturing and a dedicated production facility due 2026, reducing supply-chain risk and production delays during regulatory review.\u003c\/p\u003e\n\u003cp\u003eThis readiness positions the company to start large-scale commercial launches immediately on approval, supporting revenue ramp and partner distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFacility completion: 2026\u003c\/li\u003e\n\u003cli\u003eReduces production delay risk\u003c\/li\u003e\n\u003cli\u003eEnables immediate commercial launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin shows 32% NASH resolution; Phase 3 readouts 2025–26, cash into 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin delivered 32% absolute NASH resolution and 25% ≥1-stage fibrosis improvement in Phase 2b; Phase 3 programs ENLIGHTEN 1\/2 and ENTRUST target 2025–2026 readouts with FDA\/EMA alignment; \u0026gt;$500M cash mid-2025 funds runway into 2027 and a 2026 commercial manufacturing facility reduces launch risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2b NASH resolution\u003c\/td\u003e\n\u003ctd\u003e32% (p\u0026lt;0.01)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFibrosis ≥1-stage\u003c\/td\u003e\n\u003ctd\u003e25% (p\u0026lt;0.05)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (mid-2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003eInto 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility completion\u003c\/td\u003e\n\u003ctd\u003e2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing 89bio’s business strategy, highlighting internal capabilities, operational gaps, market opportunities, and external risks shaping its future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of 89bio for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependence on a Single Lead Asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company’s valuation and future hinge largely on pegozafermin; as of Q3 2025 89bio (NASDAQ: ETNB) derived ~85% of its enterprise value and reported $0 revenue, so pego setbacks would sharply cut market cap. Any clinical delay or FDA rejection for NASH, severe hypertriglyceridemia, or lipodystrophy indications could trigger catastrophic share declines given limited pipeline diversification. This single-asset risk makes the firm high-risk for investors and partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial and Growing Net Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a clinical-stage biopharmaceutical firm, 89bio reported net losses exceeding $100 million per quarter in 2025, driven by heavy R\u0026amp;D and global Phase 3 expenditures.\u003c\/p\u003e\n\u003cp\u003eThese quarterly deficits are likely to persist or widen as the company advances toward commercialization and scales pivotal trials across regions.\u003c\/p\u003e\n\u003cp\u003eThe high cash burn—over $400 million annualized at 2025 run-rate—requires tight financial management to prevent premature cash depletion and potential dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLack of Commercial Infrastructure and Experience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio lacks established sales, marketing, and distribution networks to match big pharma; top rivals spend $1–2B annually on commercial ops while 89bio's FY2024 cash burn was about $64M, highlighting the scale gap.\u003c\/p\u003e\n\u003cp\u003eBuilding global commercial capabilities from scratch is complex and costly—industry estimates put a global launch at $200–500M over 3–5 years—creating material execution risk for a company with limited commercial track record.\u003c\/p\u003e\n\u003cp\u003eThe firm must rapidly hire experienced commercial teams or secure a strategic partner; without a partner, timeline delays and higher per-patient acquisition costs could pressure projected revenues and raise financing needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Managing Global Phase 3 Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe scale of enlighten and entrust sites in countries major logistical strain coordinating cros regulatory filings supply chains raises fixed costs risks timeline slips.\u003e\n\u003cpmanaging global data integrity enrollment and site compliance needs advanced monitoring oversight industry benchmarks show phase median delays of months when operations falter.\u003e\n\u003cpany operational failure could push pivotal readouts past projected timelines affecting cash burn had year-end and valuation.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHundreds sites, 20+ countries\u003c\/li\u003e\n\u003cli\u003eRequires advanced CRO ops and 24\/7 monitoring\u003c\/li\u003e\n\u003cli\u003eIndustry median phase 3 delay 6–9 months\u003c\/li\u003e\n\u003cli\u003eMissed readouts risk cash runway and valuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pany\u003e\u003c\/pmanaging\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Highly Volatile Therapeutic Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio’s focus on MASH (metabolic dysfunction-associated steatohepatitis) and SHTG (severe hypertriglyceridemia) ties its fate to areas with high clinical failure: MASH phase III failure rates historically ~70% and SHTG trials show wide biomarker variability, raising commercial risk.\u003c\/p\u003e\n\u003cp\u003eIf pegozafermin hits biological hurdles, 89bio lacks alternate therapeutic pillars; the company held cash of $86.8M on Sep 30, 2024, which may be insufficient for prolonged pivots or expensive late-stage trials.\u003c\/p\u003e\n\u003cp\u003eThe narrow therapeutic scope magnifies investor sensitivity: a single negative trial could cut valuation sharply given no diversified pipeline or partnered revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh attrition: MASH ~70% phase III failure\u003c\/li\u003e\n\u003cli\u003eCash runway concern: $86.8M (Sep 30, 2024)\u003c\/li\u003e\n\u003cli\u003eNo alternate therapeutic areas or marketed products\u003c\/li\u003e\n\u003cli\u003eTrial biomarker variability increases regulatory\/commercial risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin concentration, cash scarcity and massive launch risk threaten valuation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: ~85% enterprise value tied to pegozafermin; $0 revenue as of Q3 2025; single-asset clinical failure could collapse valuation. Cash\/runway: $86.8M cash (Sep 30, 2024) vs \u0026gt;$400M annualized burn in 2025—high dilution risk. Operational strain: hundreds sites in 20+ countries; Phase 3 median delays 6–9 months. Commercial gap: no sales infrastructure; launch cost est. $200–500M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePegozafermin % EV\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$0 (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$86.8M (Sep 30, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBurn\u003c\/td\u003e\n\u003ctd\u003e~$400M annualized (2025 run-rate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 delay median\u003c\/td\u003e\n\u003ctd\u003e6–9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch cost estimate\u003c\/td\u003e\n\u003ctd\u003e$200–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e89bio SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth, editable version. You’re viewing a live preview of the real SWOT file; the complete, detailed document becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752734765433,"sku":"89bio-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/89bio-swot-analysis.png?v=1772244592","url":"https:\/\/matrixbcg.com\/products\/89bio-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}